Integrating Vamorolone Into the Duchenne Treatment Algorithm

Across this sponsored series, experts examine how vamorolone is being incorporated into the broader therapeutic landscape of Duchenne muscular dystrophy. The discussions highlight not only clinical trial findings, but also how this therapy is influencing real-world decision-making, long-term planning, and evolving standards of care.

As treatment options for Duchenne muscular dystrophy continue to expand, corticosteroids remain a foundational component of care. In this episode, Migvis Monduy, MD, a pediatric neurologist and medical director of the Cerebral Palsy and Neuromotor Center at Nicklaus Children’s Hospital, reflects on how vamorolone is being positioned within today’s treatment algorithm and how its availability is shaping conversations in clinic.

Drawing from her experience managing patients across different stages of disease, Monduy discusses how clinicians are approaching steroid-naïve young patients as well as older individuals who previously discontinued therapy due to side effects. The conversation highlights how tolerability, sustained efficacy, and long-term planning intersect when selecting and revisiting steroid therapy in Duchenne care.